ABOUT US

Gesynta Pharma’s drug candidates show potential in a range of diseases

Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and pain, thereby providing safe and efficacious treatments for several serious diseases. In a short time, Gesynta Pharma’s strong management team and renowned board of directors have combined excellence in research and development with suave entrepreneurship to build a robust scientific platform and clinical pipeline. With a portfolio of drug candidates with a unique mechanism of action, Gesynta Pharma stands well prepared for its continued value creation.
Read more about our development projects
Experienced team with excellent track record
  • Board members and management of Gesynta Pharma have extensive experience from leading positions in major pharmaceutical companies, as well as deep knowledge about all phases of drug development from discovery to the commercialization of approved products.
  • The company has presented positive study outcomes and generated a robust financial foundation for its continued value creation activities.
A strong investor base
  • Gesynta Pharma has a solid financial situation. Owners include reputable institutional investors such as Industrifonden, Linc, and Hadean Ventures, as well as several successful life science industry entrepreneurs.
A solid clinical pipeline based on drug candidates with a unique mode of action
  • Gesynta Pharma’s drug candidates target both rare diseases as well as major diseases with large patient populations.
  • The high unmet medical needs addressed by the company’s drug candidates imply significant commercial potential on the global market.
Lead compound GS-248 in clinical Phase II
  • In preclinical studies, the lead drug candidate GS-248 has shown potent and efficient anti-inflammatory and pain-relieving effects.
  • In a recently concluded Phase II study no significant effects were seen compared to placebo in Raynaud’s phenomenon or peripheral blood flow in patients with systemic sclerosis. However, the study confirmed the tolerability and safety profile, pharmacokinetics, and unique ability of GS-248 to inhibit mPGES-1 and thus modify prostaglandin profile.
  • Collectively, the data strengthens the rationale to progress the development of the drug candidate in other chronic inflammatory diseases where mPGES-1 plays a key role.
Second-generation drug candidates with the potential to address other complex diseases
  • Gesynta Pharma’s next generation of pharmacological treatments present a broad range of opportunities based on unique anti-inflammatory and pain-relieving properties.
  • The first compound in this next generation series, GS-073, is expected to enter clinical phase I in 2023

To reach Gesynta Pharma, please visit Contact.

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.